Rivoceranib, which was selected as the Best of
ESMO in 2019, was selected as the highlight paper at ESMO 2020 and
recognized its potential as a global new drug.
After ESMO Virtual
Congress 2020 ended, the International Liver Cancer Association
(ILCA) and Univadis (Medscape) selected Rivoceranib's liver cancer and non-small
cell lung cancer (NSCLC) clinical papers (combination therapy) as their
highlights. Since this year's event was held online, there was no separate
highlight session (Best of ESMO), and it was individually selected by the external
conference and professional online website.
A
combined dose of Rivoceranib and Camrelizumab were given to 70 patients subject
to primary treatment and 120 patients subject to secondary treatment at 25
hospitals. In the primary care patient group, PFS 6.4 months, ORR 46% and DCR
79%, and in the secondary care, PFS 5.5 months, ORR 25% and DCR 76% results
were produced, resulting in very significant clinical results.
In particular, the ORR
value for primary treatment resulted in superior results compared to existing
treatments.
In addition, in the
case of lung cancer, Rivoceranib and EGFR target Iressa single therapy were
compared with Rivoceranib as primary treatment for non-small cell lung cancer
for patients with EGFR Exxon 19 defects or L858R mutations, and the combined
therapy for Rivoceranib and Iressa showed a more meaningful result of 10.2 months
than the mPFS.
Chairman Jin Yang-gon of
HLB said yesterday at the Korea Investment Festival 2020 hosted by Korea
Economic TV that “The publication of 23 papers proving the efficacy of
Rivoceranib at the prestigious European Cancer Society is a phenomenal
achievement”, adding “the marketing of more than five anti-cancer drugs
within five years will be reachable due to the growth of sales in Apealea and the
expansion of the indication of Rivoceranib”. He also said, "In particular,
the 3rd phase of global clinical trial of Rivoceranib aimed at liver cancer primary
treatments are rapidly progressing, and the possibility of success is very
high."